Early ASCT in lenalidomide / bortezomib / dexamethasone therapy followed by lenalidomide maintenance, significantly improves PFS for newly diagnosed MM
Exa-cel gene-editing therapy is associated with increase in foetal and total Hb in transfusion-dependent β-thalassemia or severe sickle cell disease patients.
Phase-3 trial shows improved PFS with venetoclax/obinutuzumab/ibrutinib therapy in fit, untreated patients with chronic lymphocytic leukaemia.
A new platform connects the spheres of medical care and health innovation. It allows caregivers to find assignments with innovation actors, including companies.
CPX-351 does not improve response, overall survival, or event-free survival compared with FLAG-Ida in AML patients with adverse cytogenetics.
Continued treatment with luspatercept, for up to 3 years, allowed more patients to experience a reduction in red blood cell transfusion burden.
Large-scale whole-genome sequencing, whole-exome sequencing, and RNA-expression profiling found new T-cell acute lymphoblastic leukaemia subtypes.
OS improves when combined with standard induction and consolidation therapy, and as continuation therapy as a single agent for up to 3 years in patients.
A subgroups analysis of patients aged 65 years or older in ZUMA-7 demonstrated axi-cel to be superior to standard-of-care for second-line treatment.
Post-trial data support caplacizumab's long-term safety and efficacy in acquired or immune-mediated thrombotic thrombocytopenic purpura patients.
Nivolumab and radiotherapy at a single lesion is well tolerated and leads to an abscopal response in most of relapsed/refractory HL cases.
The phase 3 MOMENTUM trial show a significant improvement in symptoms, spleen size, and anaemia measures with momelotinib over danazol.
Phase-3 ATLAS trial shows the post-transplant maintenance therapy benefit of carfilzomib, lenalidomide, and dexamethasone over lenalidomide.
AML has high patient-to-patient treatment response variability. Pharmacoscopy allows ex vivo drug-response profiling of tumour cells, enabling tailored treatments.
In 1983 and 1986, the British police struggle with two murders. Until geneticist Dr. Alec Jeffreys brought us RFLP. Genetic fingerprinting was born.
After third-line failure, a 61-year-old female patient with metastatic pancreatic ductal adenocarcinoma received off-label monotherapy with olaparib.
OVer two years into the pandemic, a global emergency medicine professionals survey reveals that 62% reported one or more COVID-19-related burnout symptoms.
The human eye has immunological peculiarities. The graft rejection rate, for example, is just 10%. For non-vascularised corneas only about 2%.
A Spanish-German team of scientists may have made a breakthrough in the search for a reliable screening method for pancreatic cancer.
Patients without statins or lipid-lowering drugs tolerance have few options to lower LDL. Researchers developed a snack that reduced LDL cholesterol by up to 40%.